Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.

This study evaluated the effect of guselkumab on moderate to severe plaque psoriasis and found that median PASI improvements increased from around 60% at week 4 to over 90% by week 12 of treatment across multiple clinical trials.

This article reviews 27 small-molecule drugs approved by the FDA in 2024, noting that among them, eight "first-in-class" drugs with breakthrough therapy status show distinct mechanisms and substantial efficacy improvements in various conditions like cancer and chronic diseases.